Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

220
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
220
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

488
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
488
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

774
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
774
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

254
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
254
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

970
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
970
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

247
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
247

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

The multifaceted aspects of sleep and sleep-wake disorders following stroke.

Revue neurologique·2023
Same author

[CAR-T cells therapy in solid tumors : where are we now ?]

Revue medicale de Liege·2022
Same author

Impact of drug consumption rooms on non-fatal overdoses, abscesses and emergency department visits in people who inject drugs in France: results from the COSINUS cohort.

International journal of epidemiology·2022
Same author

Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.

Acta clinica Belgica·2021
Same author

[Immunotherapy for head and neck squamous cell carcinoma].

Revue medicale de Liege·2021
Same journal

[Nature prescriptions and health promotion : sharing experience from primary care].

Revue medicale de Liege·2026
Same journal

[Eco-health: shared perspectives on primary care practice].

Revue medicale de Liege·2026
Same journal

[The strategic role of primary care in emerging diseases : surveillance, research, and preparedness].

Revue medicale de Liege·2026
Same journal

[Environmental impact of medicines and approaches for more eco responsible use].

Revue medicale de Liege·2026
Same journal

[Climate change and skin].

Revue medicale de Liege·2026
Same journal

[From Silent Spring to neuronal silence : pesticides and neurodegenerative diseases].

Revue medicale de Liege·2026
See all related articles

Related Experiment Video

Updated: Aug 26, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

[Apalutamide, Erleada®].

B Sautois1, C Denis1

  • 1Service d'Oncologie médicale, CHU Liège, Belgique.

Revue Medicale De Liege
|October 13, 2022
PubMed
Summary
This summary is machine-generated.

Apalutamide improves survival for advanced prostate cancer patients when added to androgen-deprivation therapy (ADT). This treatment offers significant overall survival benefits with no negative impact on quality of life for metastatic or nonmetastatic castration-resistant prostate cancer.

Keywords:
ApalutamideMetastatic prostate cancerNonsteroidal antiandrogen agentOverall survivalAndrogen deprivation therapy

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

596
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.1K

Related Experiment Videos

Last Updated: Aug 26, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

596
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.1K

Area of Science:

  • Oncology
  • Urology

Background:

  • Androgen-deprivation therapy (ADT) is standard for advanced prostate cancer.
  • Castration-resistant prostate cancer (CRPC) eventually develops in most patients.
  • Newer agents improve outcomes in metastatic and nonmetastatic CRPC.

Purpose of the Study:

  • To evaluate the efficacy of apalutamide in advanced prostate cancer.
  • To assess apalutamide's impact on overall survival (OS) and quality of life (QoL).

Main Methods:

  • Apalutamide, a nonsteroidal antiandrogen, targets the androgen receptor.
  • Clinical trials investigated apalutamide added to ADT in metastatic and nonmetastatic CRPC settings.

Main Results:

  • Apalutamide improved OS by 35% in metastatic prostate cancer patients receiving ADT.
  • Apalutamide demonstrated a 14-month OS improvement in nonmetastatic CRPC with short PSA doubling time.
  • These survival benefits were achieved without compromising quality of life.

Conclusions:

  • Apalutamide is an effective oral treatment for advanced prostate cancer when combined with ADT.
  • Apalutamide offers significant survival advantages in both metastatic and nonmetastatic CRPC.
  • Apalutamide is well-tolerated with manageable side effects.